Search Results
PHA690509 10mg 10mg | Purity Not Available
Adooq Bioscience
LEE011 50mg 50mg | Purity Not Available
Adooq Bioscience
LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
More Information Supplier PageLEE011 25mg 25mg | Purity Not Available
Adooq Bioscience
LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
More Information Supplier PageLEE011 10mg 10mg | Purity Not Available
Adooq Bioscience
LEE011 is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity.
More Information Supplier PagePF-3635659 5mg 5mg | Purity Not Available
Adooq Bioscience
PF-3635659 25mg 25mg | Purity Not Available
Adooq Bioscience
PF-3635659 10mg 10mg | Purity Not Available
Adooq Bioscience
PKR Inhibitor 50mg 50mg | Purity Not Available
Adooq Bioscience
PKR Inhibitor is an oxindole/imidazole derivative that binds the ATP-binding site of PKR and blocks autophosphorylation with an IC50 value of 186-210 nM.3 PKR Inhibitor protects human neuroblastoma cells against cell damage triggered by tunicamycin-mediated endoplasmic reticulum stress.
More Information Supplier PagePKR Inhibitor 25mg 25mg | Purity Not Available
Adooq Bioscience
PKR Inhibitor is an oxindole/imidazole derivative that binds the ATP-binding site of PKR and blocks autophosphorylation with an IC50 value of 186-210 nM.3 PKR Inhibitor protects human neuroblastoma cells against cell damage triggered by tunicamycin-mediated endoplasmic reticulum stress.
More Information Supplier Page